Growing community of inventors

Boston, MA, United States of America

Arja Kaipainen

Average Co-Inventor Count = 5.12

ph-index = 5

The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.

Forward Citations = 177

Arja KaipainenKari Alitalo (4 patents)Arja KaipainenKatri Pajusola (3 patents)Arja KaipainenJaana Korhonen (3 patents)Arja KaipainenOlga Aprelikova (3 patents)Arja KaipainenElina Armstrong (3 patents)Arja KaipainenReija Valtola (1 patent)Arja KaipainenRejia Valtola (1 patent)Arja KaipainenKarai Alitalo (1 patent)Arja KaipainenMarja-Terttu Matikainien (1 patent)Arja KaipainenLolla Jussila (1 patent)Arja KaipainenLotta Jussila (1 patent)Arja KaipainenArja Kaipainen (5 patents)Kari AlitaloKari Alitalo (72 patents)Katri PajusolaKatri Pajusola (9 patents)Jaana KorhonenJaana Korhonen (5 patents)Olga AprelikovaOlga Aprelikova (3 patents)Elina ArmstrongElina Armstrong (3 patents)Reija ValtolaReija Valtola (1 patent)Rejia ValtolaRejia Valtola (1 patent)Karai AlitaloKarai Alitalo (1 patent)Marja-Terttu MatikainienMarja-Terttu Matikainien (1 patent)Lolla JussilaLolla Jussila (1 patent)Lotta JussilaLotta Jussila (1 patent)
..
Inventor’s number of patents
..
Strength of working relationships

Company Filing History:

1. Ludwig Institute for Cancer Research Limited (2 from 525 patents)

2. Other (1 from 832,843 patents)

3. Orion Corporation (1 from 178 patents)

4. Vegenics Pty Limited (1 from 22 patents)

5. Licentia, Ltd. (1 from 20 patents)

6. Helsinki University Licensing, Ltd. (1 from 15 patents)


5 patents:

1. 8444957 - Methods of screening for neoplastic disease states

2. 7034105 - FLT4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy

3. 6824777 - Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy

4. 6107046 - Antibodies to Flt4, a receptor tyrosine kinase and uses thereof

5. 5776755 - FLT4, a receptor tyrosine kinase

Please report any incorrect information to support@idiyas.com
idiyas.com
as of
12/30/2025
Loading…